Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN1202 for CRP Reduction in Patients with ASCVD Risk Factors
NCT00715169Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2005
- Primary completion
- Apr 2006
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of plozalizumab in atherosclerosis, sponsored by Millennium Pharmaceuticals. Started Aug 2005; status: completed.
02
Drugs
plozalizumab
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT00715169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00715169.